Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/60066
Title: Caffeine Use in Preterm Neonates: National Insights Into Turkish Nicu Practices
Authors: Unal, Sezin
Beken, Serdar
Ince, Deniz Anuk
Turan, Ozden
Toygar, Ayse Korkmaz
Ecevit, Ayse
Akcan, Abdullah Baris
Akin, Mustafa Ali
Aktas, Selma
Ciftdemir, Nukhet Aladag
Altuncu, Emel
Altunhan, Huseyin
Arcagok, Baran Cengiz
Armangil, Didem
Ozer, Esra Arun
Aydin, Banu
Bezirganoglu, Handan
Bilgin, Leyla
Calisici, Erhan
Ozdemir, Ozmert
Keywords: Caffeine
Premature Neonate
Apnea Of Prematurity
Neonatal Intensive Care Unit
Guideline
Publisher: Frontiers Media Sa
Abstract: Objective: Caffeine is a proven medication used for the prevention and treatment of apnea in premature infants, offering both short- and long-term benefits. International guidelines provide a range of recommendations regarding the preterm population eligible for caffeine prophylaxis, including the timing, dosage, and duration of treatment. Our national guidelines, published prior to the most recent updates of the international guidelines, recommend the use of caffeine citrate starting from the first day after delivery for preterm infants with a gestational age of <28 weeks. For infants up to 32 weeks, if positive pressure ventilation is required, the decision should be made on an individual basis. This study aims to describe the variability in caffeine usage across neonatal intensive care units in our country. Methods: An online survey was sent to neonatologist who are members of the Turkish Neonatology Society to describe the variability in caffeine usage in neonatal intensive care units in our country. Results: We collected responses from 74 units. Prophylactic caffeine usage was observed as; GA <= 27(6/7): 98.6%, GA 28(0/7)-28(6/7): 89.0%, GA 29(0/7)-29(6/7): 75.3%, GA 30(0/7)-31(6/7): 53.4%. 62.2% of units reported administering loading dose within the first two hours. The initial maintenance dose was 5 mg/kg in 64.8% of units, 10 mg/kg in 32.4% of units, and intermediate dose in 5.3% of units. 47.3% of units reported no routine dose adjustment. The postmenstrual age that caffeine treatment was stopped was found to be 34 (min-max; 32-36) weeks for infants without apnea and respiratory support, 36 (min-max; 34-52) weeks for infants without apnea but any respiratory support. The time to discharge after treatment cessation was found as; 1-4 days: 37.8%, 5-7 days: 68.9%. Among the 56 units with multiple responsible physicians, 32.1% reported intra-unit variations. Conclusion: The significant differences in caffeine usage characteristics between and within units highlight the need for clear recommendations provided by standardized guidelines.
Description: Ulu, Ersin/0000-0002-9798-2367
URI: https://doi.org/10.3389/fped.2025.1492716
https://hdl.handle.net/11499/60066
ISSN: 2296-2360
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
fped-1-1492716.pdf1.66 MBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

10
checked on May 26, 2025

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.